pm-01183 has been researched along with Rhabdomyolysis* in 1 studies
1 other study(ies) available for pm-01183 and Rhabdomyolysis
Article | Year |
---|---|
U.S. Food and Drug Administration Analysis of Newly Identified Adverse Events With Lurbinectedin: Extravasation, Rhabdomyolysis, and Tumor Lysis Syndrome.
Topics: Databases, Factual; Humans; Lung Neoplasms; Rhabdomyolysis; Tumor Lysis Syndrome; United States; United States Food and Drug Administration | 2022 |